Huntsville, ALNCT06566170Now EnrollingIRB Ready

Alzheimer Disease Clinical Trial in Huntsville, AL

Access cutting-edge alzheimer disease treatment through this clinical trial at a research site in Huntsville. Study-provided care at no cost to qualified participants.

Sponsored by Eli Lilly and Company

Quick Self-Assessment

See if you qualify for this Huntsville location

Preparing your pre-screening questions…

Expert Care in Huntsville

Access alzheimer disease specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related alzheimer disease treatment provided free

Apply for This Huntsville Location

Check if you qualify for this alzheimer disease clinical trial in Huntsville, AL

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Huntsville

    Convenient for AL residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Huntsville site if eligible
  4. 4Begin participation

About This Alzheimer Disease Study in Huntsville

The main purpose of this study is to evaluate the long-term effectiveness of donanemab plus usual care versus usual care alone in participants with early symptomatic AD. The study will employ a prospective, observational cohort design with participant management resembling real-world practice to the greatest extent possible via prospective assessments and linkage to historical and prospective electronic health records. The study will last about 273 weeks and may include up to 28 visits.

Sponsor: Eli Lilly and Company

Who Can Participate

Inclusion Criteria

Participants
are under care for presumed mild cognitive impairment (MCI) or mild dementia stage of AD (Note: neither a biomarker-based diagnosis of AD nor a diagnosis in electronic health records \[EHR\] is required prior to screening)
have a Telephone Interview for Cognitive Status (TICS) score of ≥21
presence of amyloid beta (Aβ) pathology supported by biomarker results (e.g., P-tau, amyloid positron emission tomography (PET), and/or cerebrospinal fluid \[CSF\]). (Note: A historical biomarker may be used for eligibility if performed within 12 months of study entry)
have a reliable study partner who is in frequent contact with the participant and will be available by telephone at designated times (every 6 months), and
have EHR data available for linkage and are willing to allow access to EHR data for the duration of the study.

Exclusion Criteria

have prior ischemic or hemorrhagic stroke(s) with an inability to independently perform any one or more basic activities of daily living (ADLs) (i.e., walking, transferring, eating, bathing, dressing, or toileting). (Note: mixed dementias with amyloid pathology are permitted)
have current or recent serious or unstable illness (other than AD) that, in the investigator's opinion, could interfere with the ability of the participant or study partner to complete the study (e.g., life expectancy of less than 36 months, requirement for long-term (\>12 months) institutional-level care, serious psychiatric illness, etc.)
are currently enrolled or intend to enroll in a clinical trial of another investigational product, and
have contraindications to donanemab, magnetic resonance imaging (MRI), or amyloid PET tracers. (Donanemab group only).

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Huntsville?

Yes, this clinical trial (NCT06566170) has an active research site in Huntsville, AL that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Alzheimer Disease Treatment Options in Huntsville, AL

If you're searching for alzheimer disease treatment options in Huntsville, AL, this clinical trial (NCT06566170) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Huntsville research site is actively enrolling participants for this clinical trial. You'll receive care from experienced alzheimer disease specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all alzheimer disease clinical trials near you to find additional studies recruiting in your area.

More Alzheimers Disease Trials in Huntsville, AL

See all alzheimers disease clinical trials recruiting in Huntsville — not just this study.

Browse Alzheimers Disease Trials in Huntsville →

Browse More Trials by Condition

Alzheimers Disease TrialsAnkylosing Spondylitis TrialsMyalgic Encephalomyelitis TrialsAll Conditions →

Ready to Join in Huntsville?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Huntsville, AL